Aesthetics

Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study

By April 29, 2020No Comments

Dermatology News

"Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study"

IncobotulinumtoxinA (Xeomin/Xeomeen/Bocouture/XEOMIN Cosmetic; botulinum toxin type A free from complexing proteins [150 kDa]; Merz Pharmaceuticals GmbH) is indicated worldwide for the correction of glabellar frown lines (GFL) and in Europe additionally for lateral periorbital lines (LPL; crow’s feet) and upper facial lines (UFL; ie, simultaneous treatment of GFL, LPL, and horizontal forehead lines [HFL]).1

The efficacy of incobotulinumtoxinA in the treatment of multiple or singular facial areas has been extensively demonstrated.2-10 With the recent surge in interest for a more holistic approach, consisting of combined treatment of GFL, HFL, and LPL in a single treatment session, there is a need for demonstrating safety and efficacy for such procedures.

This study provides strong evidence for the safety and tolerability of repeat-dose treatments with incobotulinumtoxinA in UFL (GFL, 20 U; HFL, 10-20 U; LPL, 24 U). A stable safety profile was demonstrated during prolonged administration and a noteworthy trend to better tolerability with continued use of incobotulinumtoxinA was established

Read More

You May Also Like

New Innovations of SkinCeuticals and Integrated Skincare

| JDD Highlights, JDD Webinars, The Latest | No Comments
Join Dr. Kachiu Lee, a board-certified cosmetic dermatologist, to learn more about new innovations of SkinCeuticals. Dr. Lee will share the latest integrated skincare science from SkinCeuticals, focusing on products…

JDD October Highlights and Editor Picks

| Atopic Dermatitis, Featured Articles, JDD Highlights, Latest News, The Latest | No Comments
Curated by the JDD Editors Missed any of our October highlights? October is our Atopic Dermatitis focused issue–start to dive in! Catch up with this curated roundup from the JDD…

JDD in the News: Pharmacy Deserts and Affordability Concerns in Atopic Dermatitis Care

| Atopic Dermatitis, Featured Articles, JDD Highlights, JDD in the Media, The Latest | No Comments
Healio profiled a July Journal of Drugs in Dermatology study on the affordability of dermatologist-recommended skincare products for atopic dermatitis. The study, “Socioeconomic Disparities in Gentle Skin Care Access for…

Leave a Reply